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Objectives. This study assessed the influence of donor age and
preexisting donor coronary artery disease on the later develop-
ment of allograft coronary artery disease, ischemic events and
overall survival.
Background. The increasing demand for heart donors has led
to a tendency to liberalize age criteria for donor acceptability.
Methods. A total of 233 consecutive heart transplant recipients
who had baseline, early postoperative and follow-up coronary
angiograms, as well as a subset of 47 patients with baseline
intracoronary ultrasound imaging recordings, were analyzed
(mean 3.8 years of follow-up). Patients were subclassified accord-
ing to the presence of donor coronary artery disease on the
baseline angiogram and stratified at age 40 years.
Results. Patients without evidence of preexisting coronary
artery disease on a baseline angiogram (n 5 219) were signifi-
cantly less likely to develop new disease than the 14 patients with
preexisting coronary artery disease (p 5 0.002). Although older
donors exhibited earlier coronary artery disease than younger
donors at 3 years of follow-up, there was no difference by 5 years
(p 5 0.25). There was no difference in survival or probability of
developing ischemic events between the groups. Baseline ultra-
sound imaging revealed substantial disease in 7 of 9 older donated
hearts, and in only 7 of 38 younger donated hearts (p 5 0.002).
Preexisting coronary artery disease, nonuse of calcium channel
blocking agents, older donor age, posttransplantation cytomega-
lovirus infection, elevated very low density lipoprotein levels and
previous ischemic heart disease in the recipient were significant
predictors of allograft coronary artery disease.
Conclusions. Heart donors with angiographic evidence of pre-
existing coronary artery disease and older donors are more likely
to develop new allograft coronary artery disease by 3 years.
However, there is no difference in patient survival or freedom from
ischemic events between younger and older donors at a mean
follow-up of 3.8 years.
(J Am Coll Cardiol 1997;29:623–9)
q1997 by the American College of Cardiology
It has been a generally accepted principle that organs used for
transplantation should be healthy and normally functioning at
the time of “harvesting” and should have a good prognosis for
long-term function. With this in mind, selection criteria for
donor hearts were established in the early era of clinical heart
transplantation and included not only freedom from any overt
cardiac disease, but also arbitrary upper age limits, usually in
the 35 to 40 year range (1–3). As heart transplantation has
come to be regarded as the treatment of choice for end-stage
heart failure in appropriate recipients, there has been an
ever-increasing demand for heart donors—a demand not met
by a seemingly fixed donor pool size (4). In this setting, there
has been a general move to expand the donor pool by
expanding donor criteria, especially by increasing the upper
age limit for acceptability (5–8). Earlier reports with short-
term follow-up have suggested no adverse effects on survival or
development of accelerated allograft coronary artery disease
with the use of older donors (8,9). In this retrospective study,
we analyzed the influence of older donor age and either
angiographic or intracoronary ultrasound imaging evidence of
donor coronary artery disease at early posttransplantation
study on the later angiographic incidence of allograft coronary
artery disease and overall survival. We also examined other
risk factors potentially related to allograft coronary artery
disease in this cohort of patients.
Methods
Study patients. A total of 256 consecutive adult patients
underwent heart transplantation at Stanford University Med-
ical Center between July 1986 and June 1993. Of these, 237
patients had baseline early posttransplantation coronary angio-
grams and form the basis of this report. Fourteen patients had
angiographic evidence of preexisting coronary artery disease at
baseline study and form the donor coronary artery disease
group. The other 223 patients had normal angiograms at
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baseline study; 219 of these 223 patients had follow-up records
available for review. The other four patients did not have
clinical or angiographic follow-up records and were excluded
from this study. These 219 patients comprise the no-donor
coronary artery disease group. The patients in the no-donor
coronary artery disease group were subclassified into those
with older versus younger donor hearts. Older donors were
defined as those $40 years of age. The older donor group
consisted of 30 patients (donor age 40 to 54 years, mean 44.86
4.9). The younger donor group received hearts from donors
,40 years old (13 to 39 years, mean 23.9 6 6.6) at the time of
brain death, and consisted of 189 patients. A subset of 47
patients with both baseline and follow-up coronary angiograms
and baseline intracoronary ultrasound imaging recordings was
also reviewed; three of them had angiographic evidence of
pre-existing coronary artery disease at baseline study, one with
older and two with younger donors.
Follow-up times range from 0.2 to 9.4 years (mean 3.8 6
2.3). There was no significant difference among mean
follow-up times for the subgroups (3.6 years in the donor
coronary artery disease group; 3.8 years in the no-donor
coronary artery disease group). The mean follow-up time for
the subset of 47 patients with both baseline angiograms and
intracoronary ultrasound imaging recordings was 2.4 6 0.9
years, and was equal for those with minimal or no intimal
thickening versus those with more advanced disease. All
participants gave written informed consent to the protocol,
which was approved by the Committee for the Protection of
Human Subjects in Research at Stanford University Medical
Center.
Study measurements. Clinical and laboratory risk fac-
tors—including recipient and donor age and gender; recipient
type of cardiac disease; donor ischemic time; number of human
leukocyte antigen (HLA) mismatches; cytomegalovirus infec-
tion after transplantation; postoperative blood pressure; num-
ber of rejection episodes during the first year after transplan-
tation; lipid profile (triglycerides, total cholesterol, low density
lipoprotein cholesterol, high density lipoprotein cholesterol
and very low density lipoprotein cholesterol); prednisone,
azathioprine and cyclosporine doses; and calcium channel
blocker use—were included in the data base. Blood pressure,
drug dosage and lipid measurements were computed for each
patient as the average of all available annual follow-up visits.
Coronary arteriography. Coronary arteriograms were per-
formed with a femoral approach, using standard angiographic
techniques at “baseline” (within 6 weeks postoperative) and
subsequently at approximately annual intervals. Multiple pro-
jections of both right and left coronary systems were obtained
after sublingual nitroglycerin premedication. Identical projec-
tions were obtained and compared in serial studies, which were
reviewed on the basis of side by side comparisons of projected
cineangiograms to detect subtle disease progression. The cri-
teria for diagnosis of angiographic allograft coronary artery
disease was the presence of any evidence of coronary lumen
narrowing. The criteria for progression of coronary artery
disease in patients with preexisting coronary artery disease
included either the development of new lesions or the progres-
sion of preexisting lesions. Quantitative angiographic measure-
ments were not used. Final interpretation was based on a
consensus of two angiographers (S.Z.G., E.L.A.).
Of the 233 patients with baseline angiographic studies, 94%
of 1-year survivors, 93% of 2-year survivors and 97% of 3-year
survivors completed the angiographic studies. Of the 47 pa-
tients with both baseline intracoronary ultrasound imaging
studies and angiograms, 95% had 1-year angiograms and 100%
of 2-year survivors and 96% of 3-year survivors had follow-up
angiograms. All patients who died or were retransplanted
because of allograft coronary artery disease had previous
angiography.
Intracoronary ultrasound. Imaging of the left anterior
descending coronary artery was performed immediately after
routine coronary arteriography using a 30-MHz ultrasound
transducer enclosed within an acoustic housing on the tip of a
1.7-mm diameter (3.5F), 135-cm long, flexible catheter (CVIS
Inc.). A mean of 2.3 segments (range 1 to 4) per patient were
recorded. Details of imaging technique and image analysis
have been reported elsewhere (10).
Vascular disease severity was classified according to our
previously reported categories (11), which take into account
both intimal thickness and degree of vessel circumference
involved. Patients were classified on the basis of their most
severely diseased site as having either minimal or no disease
(class 1/2) or moderate or severe disease (class 3/4). The left
anterior descending coronary artery was imaged in all 47
patients; the left circumflex coronary artery was also studied in
four patients. Only data from the left anterior descending
coronary artery were analyzed in this study.
Immunosuppressive protocol. All patients received triple
immunosuppression with cyclosporine, azathioprine and pred-
nisone. After September 1986, patients who consented were
randomized to receive diltiazem or no calcium blocker shortly
after the operation. Nine patients (64%) in the donor coronary
artery disease group and 98 patients (44.9%) in the no-donor
coronary artery disease group received diltiazem; 18 patients
(58.1%) in the older donor group and 80 patients (42.6%) in
the younger donor group received diltiazem. All patients
received aspirin and dipyridamole. Antihypertensive therapy
was generally similar in the subgroups, although angiotensin-
converting enzyme inhibitors were used more often in the
patients who did not receive diltiazem.
Criteria for diagnosis of cytomegalovirus infection. Cyto-
megalovirus infection after transplantation was defined for
purposes of this study by any of the following: seroconversion
of a previously cytomegalovirus-seronegative patient; fourfold
rise in a previously positive cytomegalovirus immunoglobulin
G titer; positive cultures for cytomegalovirus; demonstration of
cytomegalovirus inclusion bodies in tissue specimens; or a
clinical illness documented to be due to cytomegalovirus.
Ischemic events. Patients were classified as having ischemic
events if they had any of the following during their postoper-
ative period: clinical diagnosis of myocardial infarction; typical
electrocardiographic evidence of Q wave myocardial infarction
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in the absence of symptoms; appearance of congestive heart
failure in a patient with an abnormal angiogram in the
presence of a normal heart biopsy; or sudden death with
autopsy evidence of allograft coronary artery disease and no
rejection.
Statistical analysis. All results are presented as mean
value 6 SD. The Kaplan-Meier method was used to calculate
probability of freedom from allograft coronary artery disease.
The Mantel-Haenszel log-rank test was used to compare the
equality of survival curves. Differences between the group
characteristics were assessed with the chi-square test for
categoric variables and two-tailed t test for continuous vari-
ables.
Analysis of the predictors of time to initial detection of
angiographic allograft coronary artery disease was carried out
using standard stepwise regression techniques on SPSS pro-
grams. One analysis included all data collectable within 3
months of transplantation, including donor features (age,
gender, cytomegalovirus serostatus and ischemic time) and
recipient features (age, gender, cause of heart failure, number
of HLA mismatches, cytomegalovirus serostatus before and
after transplantation and calcium channel blocker use). A
second analysis included, in addition to the donor and recipi-
ent characteristics, additional data that could only be collected
in 1-year survivors. This follow-up information included the
number of rejection episodes during the first year after trans-
plantation, blood lipid measurements (triglycerides, total cho-
lesterol, low density lipoprotein cholesterol, high density li-
poprotein cholesterol and very low density lipoprotein
cholesterol), immunosuppressive medication dosage (azathio-
prine, prednisone and cyclosporine) and blood pressure (sys-
tolic and diastolic). There were 195 patients with donor and
recipient data collectable within 3 months of transplantation
and 144 one-year survivors with one or more years of complete
follow-up results available. Significant associations were de-
fined by p , 0.05.
Results
Fourteen (6%) of the 233 patients with baseline angio-
graphic studies showed some evidence of coronary artery
disease. Of the 47 patients with both baseline angiograms and
intracoronary ultrasound imaging studies, 14 patients (28%)
had class 3 or 4 intimal thickening. Of these 14 patients, only
3 (21%) had abnormal angiograms. These results confirm the
known higher sensitivity of intracoronary ultrasound imaging
compared with angiography in detecting intimal thickening.
Of the 14 patients with abnormal baseline angiograms (10%
to 40% stenosis), 6 did not show progression at any time during
follow-up and eight did show progression. Of the latter group,
all eight patients developed new lesions and four of the eight
patients also had progression in preexisting lesions. Three of
these eight patients showed lesion progression to .50%
stenosis—52%, 62% and 80% at 2, 3 and 4 years, respective-
ly—after transplantation. One patient had an acute myocardial
infarction at 5 years, and the other two patients underwent
retransplantation 5 and 6 years after the operation.
When patients with and without baseline angiographic
abnormalities are compared, it is clear that those with baseline
coronary artery disease have an increased probability of devel-
oping later progressive allograft coronary artery disease. Fig-
ure 1 demonstrates 95%, 89%, 78% and 67% freedom from
new allograft coronary artery disease at 1, 2, 3 and 4 years,
respectively, in patients with normal baseline angiograms as
compared with 86%, 71%, 37% and 37% freedom from
progression of coronary artery disease in patients with abnor-
mal baseline angiograms (p 5 0.002). In a similar analysis,
patients with normal baseline angiograms were subclassified
into groups with younger versus older donors. Patients with
older donor hearts had an increased probability of developing
allograft coronary artery disease by 3 years after transplanta-
tion (p 5 0.04), but the disease incidence in younger versus
older donor recipients was no longer significantly different in
the subsequent 3 years of follow-up (Fig. 2). Ninety-six per-
cent, 81%, 56% and 52% of patients in the younger donor
group versus 92%, 64%, 56% and 56% of patients with older
donor hearts were free from allograft coronary artery disease
at 1, 3, 5 and 6 years, respectively, after transplantation. The
results shown in Figure 2 suggest earlier onset of coronary
artery disease in older donor hearts, but the convergence of the
curves is in accord with the eventual inevitability of the disease.
Table 1 lists the baseline intracoronary ultrasound imaging
classes in the subset of 47 patients studied with this modality,
subclassified according to donor age, and shows a significantly
increased prevalence of more advanced classes of intimal
thickening in older donors. Table 2 shows the incidence of later
development of progressive angiographic allograft coronary
artery disease in the groups subclassified according to the
presence and severity of baseline intimal disease. There is no
significant difference between the groups (p 5 0.87).
Multivariate Cox regression analysis was used to identify
Figure 1. Graph comparing time-related percent freedom from new or
progressive allograft coronary artery disease (CAD) in patients with
and those without donor coronary artery disease. TxCAD 5 allograft
coronary artery disease.
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potential risk factors associated with development (or progres-
sion) of allograft coronary artery disease (Table 3). This
analysis showed that donor preexisting coronary artery disease,
nonuse of calcium channel blockers, older donor age, previous
ischemic heart disease and elevated very low density lipopro-
tein cholesterol levels were associated with earlier develop-
ment of allograft coronary artery disease. This multivariate
analysis, which included all follow-up data, showed that a
positive cytomegalovirus serology in the recipient before trans-
plantation is associated with earlier onset of coronary artery
disease. Another multivariate analysis was performed with
truncation at 4 years because only 28% of the original cohort
remained alive and free of coronary artery disease beyond 4
years. In this truncated analysis, the occurrence of cytomega-
lovirus infection after transplantation was the highest ranked
predictor of a shorter interval to onset of coronary artery
disease (p 5 0.007).
Comparison of actuarial freedom from ischemic events
showed no significant differences between the donor coronary
artery disease and no-donor coronary artery disease groups
(p 5 0.61), or between the younger and older donor groups
(p 5 0.73). Actuarial survival curves for the two subsets of
older versus younger donor hearts also showed no difference,
with a mean follow-up of 3.8 years (p 5 0.64). In addition,
there was no significant difference in survival between the
donor coronary artery disease and no-donor coronary artery
disease groups (p 5 0.26).
A variety of other potential coronary artery disease risk
factors were compared between the groups (Table 4). No
significant differences were found between the no-donor cor-
onary artery disease and donor coronary artery disease groups.
In comparing of these same factors in older and younger donor
groups, there were no significant differences, except a higher
level of HLA mismatch in the younger donor group, as listed in
Table 4.
Discussion
This retrospective analysis of 233 consecutive adult heart
transplant recipients strongly suggests that the use of donor
hearts with preexisting coronary artery disease is associated
with a higher incidence of progression and development of
allograft coronary artery disease after transplantation, but not
with a different probability of survival or ischemic events with
a mean follow-up of 3.8 years. Because the number of patients
with disease at baseline was small, it is possible that larger
numbers or longer follow-up will, in fact, see these curves
diverge. The fact that older donor age, at least as defined by
our arbitrary cutoff point of age 40 years, was not associated
with an increased prevalence of later coronary artery disease
on angiography or with a difference in later ischemic events or
overall survival, is an important point of this study. Both
findings suggest that the use of carefully selected older donor
hearts can safely increase the size of the donor pool, confirm-
ing earlier reports of short-term good results with older donors
(8,9).
Cytomegalovirus infection and allograft coronary artery
disease. The significance of recipient cytomegalovirus infec-
tion as a risk factor for development of coronary artery disease
is of interest because postoperative cytomegalovirus infection
was first reported by our group to correlate with later devel-
opment of coronary artery disease on angiography in heart
transplant recipients (12). Our earlier study described patients
transplanted between 1980 and 1988, and differs from the
current report of patients transplanted between 1986 and 1993,
in that this latter group was influenced by the introduction of
cytomegalovirus prophylaxis therapy with ganciclovir in 1987,
Figure 2. Graph showing comparison of time-related percent freedom
from new allograft coronary artery disease (CAD) in patients receiving
hearts from younger (,40 years) and older ($40 years) donors in
patients with normal baseline angiograms. TxCAD 5 allograft coro-
nary artery disease.
Table 1. Comparison of Intimal Thickening Detected by




p ValueClass 1/2 Class 3/4
Younger pts (n 5 38) 31/38 (82%) 7/38 (18%) 0.002
Older pts (n 5 9) 2/9 (22%) 7/9 (78%)
ICUS 5 intracoronary ultrasound; pts 5 patients.
Table 2. Development of Angiographically Apparent Coronary





p ValueNo TxCAD TxCAD
1/2 (n 5 33) 26/33 (79%) 7/33 (21%) 0.87
3/4 (n 5 14) 10/14 (71%) 4/14 (29%)
ICUS 5 intracoronary ultrasound; TxCAD 5 allograft coronary artery
disease.
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first as part of a randomized trial (until 1990) and subsequently
as routine therapy (13). Despite current use of cytomegalovirus
prophylaxis, the overall incidence of cytomegalovirus infection
after transplantation in this report is 31% compared with
30.2% for the 1980 to 1988 cohort using the same diagnostic
criteria. The results of this study suggest that cytomegalovirus
infection after transplantation is still a major factor in early
onset of allograft coronary artery disease (14), despite the use
Table 3. Multivariate Stepwise Regression Analysis of Time to Detection of Angiographic Allograft Coronary Artery Disease in a Consecutive
Series of 233 Heart Transplant Recipients
All Transplant Recipients
(includes data collectable immediately
after transplantation; 195 patients available for analysis)
1-Year Survivors
(includes data collectable within 12 months
after transplantation; 144 patients available for analysis)
Donor features: age, CAD, CMV and ischemic time Donor features: age, CAD, CMV and ischemic time
Recipient features: age, gender, CAD, CMV, HLA mismatch and
calcium blocker use
Recipient features: Age, gender, CAD, CMV, HLA mismatch, calcium
blocker use, lipids, rejection episodes, blood pressure and
immunosuppressive medications
Variable p Value Variable p Value
Donor CAD at entry 0.0002 Donor CAD at entry 0.003
Calcium blocker nonuse 0.001 Calcium blocker nonuse 0.0001
Older donor age 0.007 Older donor age 0.002
Recipient heart disease: ischemic 0.03 Recipient pre-Tx CMV serology positive 0.01
VLDLC 0.004
CAD 5 coronary artery disease; CMV 5 cytomegalovirus infection; HLA 5 human leukocyte antigen; Tx 5 transplantation; VLDLC 5 very low density
lipoprotein cholesterol.







Recipient age (yr) 496 12.9 47.1 6 11.9 0.26
Donor age (yr) 44.86 4.0* 23.9 6 6.6* , 0.001
Recipient gender (% male) 76 85 0.31
Original cardiac disease
Coronary artery disease 18 82
Cardiomyopathy 12 91
Other 0 15 0.11
HLA mismatch (no. of loci)
A 1.1 6 0.6† 1.4 6 0.6† 0.04
B 1.3 6 0.7 1.4 6 0.6 0.51
A 1 B 2.5 6 1.1 2.9 6 0.9 0.08
Ischemic time (min) 1486 46 158 6 47 0.27
CMV infection before Tx
Recipient CMV positive 18 111 0.89
Donor CMV positive 16 89 0.69
CMV infection after Tx
By serology 11 56 0.55
Symptom 7 31 0.51
No. of rejection episodes (first year after operation) 1.96 1.2 1.9 6 1.1 0.99
Blood pressure (mm Hg)
Systolic 136 6 13 136 6 14 0.94
Diastolic 89 6 9 89 6 9 0.74
Prednisone dose (mg/kg body weight per day) 0.156 0.1 0.16 6 0.1 0.55
Cyclosporine dose (mg/kg per day) 3.66 1.5 4.1 6 2.2 0.30
Azathioprine dose (mg/kg per day) 1.66 0.8 1.7 6 0.8 0.65
Plasma triglyceride (mg/dl) 1916 111 202 6 121 0.70
Total cholesterol (mg/dl) 2156 41 231 6 59 0.21
HDL-C (mg/dl) 456 10 45 6 16 0.99
LDL-C (mg/dl) 1356 36 144 6 41 0.34
VLDL-C (mg/dl) 396 24 40 6 28 0.82
Data presented are mean value 6 SD or number of patients, unless otherwise indicated. CMV 5 cytomegalovirus;
HDL-C 5 high density lipoprotein cholesterol; HLA 5 human leukocyte antigen; LDL-C 5 low density lipoprotein
cholesterol; Tx 5 transplantation; VLDL-C 5 very low density lipoprotein cholesterol.
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of cytomegalovirus prophylaxis and its clinical success in
ameliorating the severity of cytomegalovirus disease. A de-
tailed evaluation of the effect of cytomegalovirus prophylaxis
on the incidence of allograft coronary artery disease is cur-
rently ongoing.
The observation that the recipient’s previous ischemic heart
disease and elevated very low density lipoprotein cholesterol
level contribute to the risk of earlier onset of coronary artery
disease suggests a role for typical atherosclerosis risk factors.
Histopathologic study of transplanted hearts shows that older
lesions exhibit features typical of ordinary complex atheromas
(15). Moreover, a 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitor has been shown to decrease the incidence
of allograft coronary artery disease (16).
Intracoronary ultrasound imaging for detection of allograft
coronary artery disease. The intracoronary ultrasound imag-
ing data presented here are preliminary, but add to the
growing body of evidence supporting the validity of intracoro-
nary ultrasound measurements as a more sensitive modality for
the detection and monitoring of allograft coronary artery
disease (11,17). Serial intracoronary ultrasound imaging data
reported from our institution suggest that the usual rate of
intimal hyperplasia in heart transplant recipients that occurs in
disease-free arteries is superimposed on any pre-existing lu-
men narrowing. The combination of preexisting and incremen-
tal hyperplasia may lead more rapidly to angiographically
detectable and ultimately clinically important lumen compro-
mise. Therefore, one does not need to invoke acceleration of
the usual rate of intimal hyperplasia in older donor hearts to
explain earlier angiographic detection of coronary lesions (18).
In our patients, we demonstrated a significantly higher
incidence of moderate to severe intracoronary ultrasound
imaging class in older donors—a finding similar to observa-
tions already reported by Tuzcu et al. (19). However, knowl-
edge of the extent to which advanced intimal thickening in
older donor hearts is associated with a higher incidence of later
allograft coronary artery disease on angiography, particularly
in patients with substantially detectable disease on intracoro-
nary ultrasound imaging, is limited by the small number of
patients and short follow-up duration. Fourteen (28%) of the
47 patients in our study group had class 3 or 4 intimal
thickening on baseline intracoronary ultrasound examinations,
and 33 patients (72%) showed class 1 or 2 intimal changes.
Therefore, by extrapolation, about one-third of donor hearts
had moderate to severe preexisting intimal thickening. This
fact limits the validity of intracoronary ultrasound for the
diagnosis of allograft coronary artery disease if patients have
not had a baseline study.
Calcium channel blocker use. In this study, the use of
calcium channel blockers was correlated with a lower incidence
of allograft coronary artery disease—a finding concordant with
our previously reported results of a randomized trial of dilti-
azem, which showed less decline in coronary artery diameter
during the first postoperative year (20) and fewer clinical
events in later years (21) in diltiazem-treated patients. These
results and others (22) suggest an important role for the use of
calcium channel blockers after transplantation, perhaps most
importantly in high risk patients such as recipients of older
donor hearts and those with any evidence of preexisting donor
coronary artery disease.
Conclusions. Cardiac donors with angiographic evidence
of pre-existing coronary artery disease have a greater tendency
to develop new allograft coronary artery disease. Despite the
higher incidence of moderate to severe intimal thickening
detected by intracoronary ultrasound found in older donors,
older donor age was not significantly associated with the
development of later allograft coronary artery disease on
angiography. There was no difference in patient survival or
freedom from ischemic events between patients with younger
versus older donor hearts at a mean 3.8 years of follow-up.
We are grateful to Ms. Anne Schwarzkopf for the collection of ICUS imaging
results.
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